Mhairi Copland

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6058870/mhairi-copland-publications-by-year.pdf
Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51 papers	2,032 citations	20 h-index	44 g-index
58 ext. papers	2,478 ext. citations	9.3 avg, IF	5.08 L-index

#	Paper	IF	Citations
51	In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial.. *Lancet Haematology,the*, **2022**, 9, e276-e288	14.6	3
50	Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial.. *Lancet Haematology,the*, **2022**, 9, e262-e275	14.6	1
49	Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial.. *Lancet Haematology,the*, **2021**,	14.6	2
48	Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape. *Leukemia*, **2021**, 35, 1229-1242	10.7	18
47	Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML. *Cell Death Discovery*, **2021**, 7, 137	6.9	3
46	The application of BH3 mimetics in myeloid leukemias. *Cell Death and Disease*, **2021**, 12, 222	9.8	9
45	ULK1 inhibition promotes oxidative stress-induced differentiation and sensitizes leukemic stem cells to targeted therapy. *Science Translational Medicine*, **2021**, 13, eabd5016	17.5	2
44	BRD4-mediated repression of p53 is a target for combination therapy in AML. *Nature Communications*, **2021**, 12, 241	17.4	11
43	A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. *Leukemia*, **2020**, 34, 1775-1786	10.7	26
42	CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. *Leukemia*, **2020**, 34, 1613-1625	10.7	22
41	The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. *Nature Reviews Cancer*, **2020**, 20, 158-173	31.3	74
40	Is There a Role for Dose Modification of TKI Therapy in CML?. *Current Hematologic Malignancy Reports*, **2019**, 14, 337-345	4.4	12
39	De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. *Lancet Haematology,the*, **2019**, 6, e375-e383	14.6	74
38	Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML). *Blood*, **2019**, 134, 3938-3938	2.2	1
37	Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy. *Blood*, **2019**, 134, 2935-2935	2.2	
36	Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. *Nature Medicine*, **2018**, 24, 450-462	50.5	69
35	Exploring Stem Cell Heterogeneity in Chronic Myeloid Leukemia. *Trends in Cancer*, **2018**, 4, 167-169	12.5	1

34	Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK. *British Journal of Haematology*, **2018**, 182, 777-788	4.5	7
33	Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML. *Blood*, **2018**, 132, 457-457	2.2	6
32	Chronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal. *Cell Death and Disease*, **2018**, 9, 927	9.8	9
31	Approaches for targeting self-renewal pathways in cancer stem cells: implications for hematological treatments. *Expert Opinion on Drug Discovery*, **2017**, 12, 465-474	6.2	7
30	Implementing the EffTox dose-finding design in the Matchpoint trial. *BMC Medical Research Methodology*, **2017**, 17, 112	4.7	22
29	De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. *Lancet Haematology,the*, **2017**, 4, e310-e316	14.6	71
28	Developing collaborations to establish a low-cost advanced diagnostic hematology laboratory in Peshawar, Pakistan. *Blood Advances*, **2017**, 1, 36-38	7.8	78
27	Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia. *Blood Advances*, **2016**, 1, 160-169	7.8	8
26	Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. *Scientific Reports*, **2016**, 6, 25476	4.9	54
25	Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. *Nature*, **2016**, 534, 341-6	50.4	141
24	Notch Pathway Activation Targets Leukemic Stem Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML). *Blood*, **2016**, 128, 3057-3057	2.2	1
23	Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia. *Scientific Reports*, **2016**, 6, 24057	4.9	5
22	Hedgehog signaling in cancer stem cells: a focus on hematological cancers. *Stem Cells and Cloning: Advances and Applications*, **2015**, 8, 27-38	2.6	32
21	CD93 Is a Novel Biomarker of Leukemia Stem Cells in Chronic Myeloid Leukemia. *Blood*, **2015**, 126, 49-49	2.2	7
20	Dual Inhibition of MDM2 and BET Cooperate to Eradicate Acute Myeloid Leukemia. *Blood*, **2015**, 126, 674-674	2.2	1
19	A Telomere-associated secretory phenotype cooperates with BCR-ABL to drive malignant proliferation of leukemic cells. *Leukemia*, **2014**, 28, 2028-39	10.7	27
18	The role of the bone morphogenetic proteins in leukaemic stem cell persistence. *Biochemical Society Transactions*, **2014**, 42, 809-15	5.1	13
17	In a 12-allele analysis HLA-DPB1 matching is associated with improved OS in leukaemic and myelodysplastic patients receiving myeloablative T-cell-depleted PBSCT from unrelated donors. *Bone Marrow Transplantation*, **2014**, 49, 657-63	4.4	8

16	EZH2 in normal and malignant hematopoiesis. *Leukemia*, **2014**, 28, 44-9	10.7	129
15	Dasatinib Plus Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) with Resistance or Suboptimal Response to a Prior Tyrosine Kinase Inhibitor (TKI): Phase I Study CA180323. *Blood*, **2014**, 124, 4539-4539	2.2	16
14	Targeting chronic myeloid leukemia stem cells. *Current Hematologic Malignancy Reports*, **2013**, 8, 14-21	4.4	10
13	Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience. *Leukemia Research Reports*, **2013**, 2, 47-50	0.6	2
12	Dasatinib for the treatment of chronic phase chronic myeloid leukemia. *Clinical Practice (London, England)*, **2013**, 10, 415-425	3	2
11	Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. *Blood*, **2013**, 122, 1293-304	2.2	98
10	How I manage priapism in chronic myeloid leukaemia patients. *British Journal of Haematology*, **2012** , 158, 155-164	4.5	32
9	Targeting hedgehog in hematologic malignancy. *Blood*, **2012**, 119, 2196-204	2.2	104
8	Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation. *Leukemia and Lymphoma*, **2012**, 53, 2474-8	1.9	19
7	Ikaros deletions are associated with poor prognosis in acute lymphoblastic leukemia. *Future Oncology*, **2009**, 5, 455-8	3.6	2
6	Chronic myelogenous leukemia stem cells: What's new?. *Current Hematologic Malignancy Reports*, **2009**, 4, 66-73	4.4	20
5	BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. *Blood*, **2008**, 111, 2843-53	2.2	108
4	Effect of Dasatinib on BCR-ABL and Src Mediated Growth Signaling in Primary CML Hematopoietic Progenitors.. *Blood*, **2007**, 110, 2944-2944	2.2	
3	Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. *Clinical Cancer Research*, **2006**, 12, 626-33	12.9	81
2	Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. *Blood*, **2006**, 107, 4532-9	2.2	542
1	Evolving molecular therapy for chronic myeloid leukaemia--are we on target?. *Hematology*, **2005**, 10, 349-59	2.2	34